Our Studies

Bowel Preparation

A study to evaluate the efficacy of a potential study drug for bowel preparation prior to a scheduled colonoscopy.

• Between 18-85 years; no bowel obstructions
• No IBD with bowel resection history, active inflammation or stricture
• No significant GI surgeries
• Must have stable diuretics, anti-hypertensive, ACE inhibitors, ARBs and chronic NSAIDs
• No uncontrolled hypertension, no severe renal insufficiency, hepatic insufficiency, cardiac insufficiency
• No insulin therapy or tricyclic antidepressants

Call Us
440.205.1225
Email Us
[email protected]
Online
Please fill out our patient recruitment form.

Celiac Disease

Study to access investigational agent for patients with symptoms on a Gluten Free Diet.

• ≥18 years old.
• Celiac diagnosis ≥ 6 months confirmed by biopsy and serology.
• Positive for HLA-DQ2 or HLA-DQ8.
• Has GI symptoms (pain, cramping diarrhea, etc.) at least once/week or 4 times/month despite gluten free diet for at least 6 months prior to screening.
• No IBD, IBS, gastroparesis, lupus.
• No Type 1 diabetes. No HbA1c > 8.5%.
• No cancer in past 5 years.

Call Kelli Holcknecht
(440) 205-1225 x 267
Email
[email protected]
Online
Please fill out our patient recruitment form.

Chrohns Disease

A study to evaluate the efficacy of a potential study drug to reduce inflammation in the digestive system.

• 18 Years of age or older
• List of current medications must be evaluated by a study coordinator for qualification

Call Kelli Holcknecht
(440) 205-1225 x 267
Email
[email protected]
Online
Please fill out our patient recruitment form.

CRC Screening

Developing new blood tests to detect Colorectal Cancer.

• Age 40+. Screening colonoscopy—no scope in past 9 years.
• No positive Cologuard or FIT in past 2 years.
• No hx of CRC, FAP, Lynch, other hereditary cancer syndromes.
• No IBD.

Call Us
440.205.1225
Email Us
[email protected]
Online
Please fill out our patient recruitment form.

Eosinophilic Esophagitis/Eosinophilic gastroenteritis

Study to assess the efficacy and safety of investigational agent, given monthly for 6 doses, in patients with moderately to severely active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) who have an inadequate response with, lost response to, or were intolerant to standard therapies.

• 18 – 80 years old.
• Baseline EDG more than 30 eosinophils/hpf in 5 hpf, inadequate or loss of response to standard therapies: PPI, antihistamines, systemic or topical corticosteroids, and diet.
• No hx of corticosteroids 4 weeks prior, no change in PPI, leukotrienes, or diet 4 weeks prior.
• No hx of IBD, celiac, achalasia, or esophageal

Call Kelli Holcknecht
(440) 205-1225 x 267
Email
[email protected]
Online
Please fill out our patient recruitment form.

Irritable Bowel Syndrome

The purpose of this study is to determine whether the investigational agent is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).

• Age 18-70.
• IBS-C or IBS-D w/ abdominal pain.
• No IBD or Celiac, no hx of CRC or diverticulitis.
• No hx of GI stricture, perforation, surgery.
• No cholecystectomy.
• No diabetes.
• No orthostatic hypotension or uncontrolled hypertension.
• No moderate or strong CYP3A4 inhibitors/inducers (e.g. fluoxetine, alprazolam, sertraline, atorvastatin, prednisone).
• No positive hx of occult blood or bacterial tests in past 6 months.

Call Kelli Holcknecht
(440) 205-1225 x 267
Email
[email protected]
Online
Please fill out our patient recruitment form.

Ulcerative Colitis

A study to evaluate the efficacy of a potential study drug to reduce inflammation in the digestive system.

• 18 Years of age or older
• List of current medications must be evaluated by a study coordinator for qualification

Call Kelli Holcknecht
(440) 205-1225 x 267
Email
[email protected]
Online
Please fill out our patient recruitment form.